^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Nasopharyngeal Carcinoma
    Drug:cisplatin (DNA synthesis inhibitor) +
    gemcitabine (DNA synthesis inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    12/08/2021
    Excerpt:
    SYSTEMIC THERAPY FOR NASOPHARYNGEAL CANCERS: Induction/Sequential Systemic Therapy...Preferred Regimens...Gemcitabine/Cisplatin...